论文部分内容阅读
目的评估S-1联合紫杉醇治疗晚期胃癌的疗效、不良反应和临床受益反应。方法 36例晚期胃癌患者,1-14d内给予S-1,80mg/m2,分2次口服(餐后服用),同时在第1、8、15d紫杉醇90mg/m2。S-1用药14d停药,14d为1个周期,紫杉醇4周为1个周期。治疗2个周期后进行疗效、不良反应及临床受益反应评价。结果全组36例可评价,完全缓解0例,部分缓解24例,稳定9例,进展3例,有效率为66.7%,不良反应率较低,临床受益反应较好。结论 S-1联合紫杉醇治疗晚期胃癌患者近期疗效较好,不良反应可以耐受,临床受益反应较好。
Objective To evaluate the efficacy, side effects and clinical benefit of S-1 combined with paclitaxel in the treatment of advanced gastric cancer. Methods Thirty-six patients with advanced gastric cancer were treated with S-1 and 80 mg / m2 within 1-14 days. The patients were given orally twice daily (after a meal) and on the first, the 15th and the 15th days respectively. S-1 drug withdrawal 14d, 14d for a cycle, paclitaxel 4 weeks for a cycle. After 2 cycles of treatment efficacy, adverse reactions and clinical benefit evaluation. Results The whole group of 36 cases can be evaluated, complete remission in 0 cases, partial remission in 24 cases, stable in 9 cases, progress in 3 cases, the effective rate was 66.7%, the adverse reaction rate is low, the clinical benefit response is better. Conclusion S-1 combined with paclitaxel in the treatment of advanced gastric cancer patients with better immediate effect, adverse reactions can be tolerated, the clinical benefit response is better.